Search clinical trials for: Debio 0932

Total 161 results

Debiopharm International SA

Completed

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

Neoplasms | Lymphoma | Cancer | Solid Tumors

France
Debiopharm International SA
Caris Life Sciences; Optimal Research (Just In Time sites)

Terminated

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Solid Tumor

United States, Spain, Austria, Czechia, Denmark, Russian Federation, United Kingdom, Greece, Norway, Korea, Republic of, France, Taiwan, Netherlands, Bulgaria, Finland, Ukraine, Australia, Brazil, Croatia, Philippines, Poland, Rom... and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck KGaA, Darmstadt, Germany

Completed

PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants

Healthy

United Kingdom
Debiopharm International SA

Recruiting

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, Switzerland
Debiopharm International SA

Not yet recruiting

A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer

Prostate Cancer
Debiopharm International SA

Completed

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Lymphoma | Cancer | Solid Tumors | Malignancy

United States
Debiopharm International SA

Completed

Study of Debio 1450 for Bacterial Skin Infections

Bacterial Infections

United States
Debiopharm International SA

Completed

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Hepatitis C

Romania, Italy, Belgium, Germany, Hungary, Taiwan, Spain, Australia, Hong Kong, Thailand, France, United States, United Kingdom, Turkey, Argentina, Russian Federation, India, Korea, Republic of, Vietnam, Poland, Mexico, Canada
Debiopharm International SA

Completed

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Bacterial Infections

United States
Debiopharm International SA

Completed

Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects

Healthy

United Kingdom
Debiopharm International SA

Completed

A Single Dose Study of Debio 1450 in Healthy Subjects

Bacterial Infections

United States
Genentech, Inc.

Completed

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

Healthy Volunteer

United States
Debiopharm International SA

Completed

Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery

Bone Diseases, Infectious

United States
Debiopharm International SA
Syneos Health

Terminated

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC] (HALO)

Non-small Cell Lung Cancer

Spain, France, United Kingdom
Debiopharm International SA

Completed

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Neoplasms | Carcinoma, Non-Small-Cell Lung

Canada, Poland, Romania
Debiopharm International SA

Recruiting

Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Netherlands, Spain
Debiopharm International SA

Terminated

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Solid Tumors

France
Debiopharm International SA

Recruiting

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)

Central Precocious Puberty

United States
Genentech, Inc.

Completed

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

Healthy Volunteer

United States
FORUM Pharmaceuticals Inc
Parexel

Completed

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Mild Cognitive Impairment | Alzheimer's Disease

United States
University Hospital, Tours

Completed

Study of Hemodynamic Conditions Measured During Hepatectomy (DEBIFOIE)

Liver Dysfunction | Circulatory; Change

France
AbbVie

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Healthy Volunteers | Generalized Anxiety Disorder (GAD) | Bipolar Disorder (BPD)

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Romania, Spain, Switzerland, Netherlands, Poland, Por...
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Harvard Medical School (HMS and HSDM)
Brigham and Women's Hospital

Active, not recruiting

Cash Benefits and Reproductive/Perinatal Health

Pregnancy Related | Miscarriage | Maternal Care Patterns

United States
Harvard Medical School (HMS and HSDM)
Brigham and Women's Hospital; Cambridge Health Alliance

Active, not recruiting

Effect of Cash Benefits on Health Care Utilization

Health Care Utilization

United States
Debiopharm International SA

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Astrocytoma, Grade III | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Spain, United States, Switzerland
Debiopharm International SA

Completed

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Diffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
Merrimack Pharmaceuticals

Completed

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

Psoriasis

United States
KinoPharma Inc.

Active, not recruiting

OM202JP Clinical Study of KNP2002

Common Wart

Japan
Merck Sharp & Dohme LLC

Completed

A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Cancer
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Head and Neck Cancer

Taiwan, United States, Korea, Republic of, Spain, Belgium
ArQule, Inc. (a wholly owned subsidiary of Merck...

No longer available

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

Growth Disorders | Proteus Syndrome | PIK3CA-Related Overgrowth Spectrum (PROS)
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma

United States, Canada
AbbVie
Gedeon Richter Plc.

Recruiting

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Healthy Participants | Generalized Anxiety Disorder (GAD)

United States
Five Eleven Pharma, Inc.
Indiana University

Active, not recruiting

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

Prostate Cancer | Prostate Cancer Recurrent

United States
Merrimack Pharmaceuticals

Completed

Phase 2 Study of MM-093 to Treat Patients With Uveitis

Uveitis

United States
Debiopharm International SA

Completed

Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial

Squamous Cell Carcinoma of the Head and Neck

France, Switzerland
University of Castilla-La Mancha

Completed

Percutaneous High Frequency Alternating Current Stimulation in Healthy Volunteers

Electrical Stimulation | Neuromodulation

Spain
University of Castilla-La Mancha

Completed

Percutaneous High Frequency Alternating Current Stimulation in Healthy Volunteers With 30kHz

Electrical Stimulation | Neuromodulation

Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more
National Institute of Neurological Disorders and...

Completed

Treatment of Parkinson's Disease With a Transdermal Skin Patch

Parkinson Disease

United States
Peking Union Medical College Hospital

Not yet recruiting

68Ga-P16-093 PET/CT Imaging in the Salivary Gland

Primary Sjögren Syndrome
Arcturus Therapeutics, Inc.
Novotech CRO

Recruiting

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

Cystic Fibrosis

New Zealand
Peking Union Medical College Hospital

Recruiting

68Ga-P16-093 PET/CT Imaging in Glioma Patients

Glioma

China
Five Eleven Pharma, Inc.

Active, not recruiting

Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

Prostate Cancer | Renal Cancer

United States
Debiopharm International SA

Completed

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106)

Solid Tumor

United States, Spain, France
Senju Pharmaceutical Co., Ltd.

Completed

Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease

Dry Eye Syndrome | Dry Eye Disease

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

United States, Australia, Brazil, Italy, United Kingdom
ArQule, Inc. (a wholly owned subsidiary of Merck...
Worldwide Clinical Trials

Terminated

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) (MOSAIC)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

United States, Australia, Italy, Spain

Search clinical trials for: Debio 0932

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations